<?xml version="1.0" encoding="UTF-8"?>
<p>The genetic determinants of neurodegenerative disease have been explored in genome-wide association studies (GWASs) (
 <xref rid="fcaa031-B47" ref-type="bibr">IMSGC and WTCCC2, 2011</xref>; 
 <xref rid="fcaa031-B45" ref-type="bibr">IMSGC, 2013</xref>, 
 <xref rid="fcaa031-B46" ref-type="bibr">2019</xref>; 
 <xref rid="fcaa031-B35" ref-type="bibr">GeM-HD Consortium, 2015</xref>; 
 <xref rid="fcaa031-B91" ref-type="bibr">van Rheenen 
  <italic>et al.</italic>, 2016
 </xref>; 
 <xref rid="fcaa031-B21" ref-type="bibr">Chang 
  <italic>et al.</italic>, 2017
 </xref>; 
 <xref rid="fcaa031-B49" ref-type="bibr">Jansen 
  <italic>et al.</italic>, 2019
 </xref>; 
 <xref rid="fcaa031-B64" ref-type="bibr">Nalls 
  <italic>et al.</italic>, 2019
 </xref>). GWASs are a tremendous resource for studying molecular pathways and drug targets, and medications with genetic support may be twice as likely to proceed from Phase I to approval (
 <xref rid="fcaa031-B65" ref-type="bibr">Nelson 
  <italic>et al.</italic>, 2015
 </xref>).
</p>
